Effects of the ellagic acid on the N-acetyltransferase activity and acetylation of 2-aminofluorene in the rat

Toxicological and Environmental Chemistry

Volumn 71, Issue 3-4, 1999, Pages 319-329

  Ho, Chin C ^a   Tsai, Huei Y ^a   Lai, Yih S ^a   Chung, Jing G ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

2 aminofluorene; Acetylation; Anti carcinogen; Carcinogenesis; Ellagic acid

Indexed keywords

EID: 0033451415     PISSN: 02772248     EISSN: None     Source Type: Journal    
DOI: 10.1080/02772249909358803     Document Type: Article

References (33)

1. Aryton, A.D. et al. (1992). Fd. Chem. Toxicol. 30, 289-295.
2. Ahn, D. et al. (1996) Carcinogenesis 17, 821-828
3. Akagi, K. et al. (1995). Cancer Letts. 94, 113-121.
4. Barch, D.H. and Rundhaugen, L.M. (1992). Hepatolo. 16, 99A.
5. Barch, D.A. et al. (1994). Biochem. Biophys. Res. Commun. 201, 1477-1482.
6. Bradford, M.M. (1976). Anal. Biochem. 72, 248-254.
7. Cartwright, R.A. et al. (1982). The role of n-acetyltransferase phenotypes in bladder cancer. Lancet II, 842-846.
8. Chung, J.G. et al. (1993). Drug Metab. Dispos. 21, 1057-1063.
9. Chung, J.G. (1998). J. Appl. Toxicol. (in press).
10. Das, M. et al. (1985). Carcinogenesis 6, 1409-1413.
11. DuSouich, P. and Courteau, H. (1981). Drug. Metab. Dispos. 9, 279-283.
12. Einisto, P. et al. (1991). Mutation Res. 259, 95-102.
13. Evans, D.A.P. (1989). Pharmacol. Ther. 42, 157-234.
14. Grant, D.M. (1992). Cancer Res. 52, 3961-3964.
15. Hein, D.W. et al. (1982). J. Pharm. and Exp. Thera. 220, 8-15.
16. Ho, C.C. et al. (1998). Toxicol. Environ. Chem. (in press).
17. Juberg, D.R. (1991). Pharmacogenetics 1, 50-57.
18. Lang, N.P. and Kadlubar, F.F. (1991). In New Horizons Biological Dosimetry (B.L. Gledhill and F. Mauro, Eds.), pp. 33-47. Wiley-Liss, New York.
19. Levy, G.N. and Weber, W.W. (1992). Carcinogenesis 13, 159-164.
20. Levy, G.N, (1993). Fund. Appl. Toxicol. 21, 23-30.
21. Mandal, S. and Stoner, G.D. (1990). Carcinogenesis 11, 55-61.
22. Minchin, R.F. et al. (1992). Biochem. Biophys. Res. Commun. 185, 839-844.
23. Reeves, R.T. (1988). Drug. Metab. Dispos. 16, 110-115.
24. Rocci Jr., M.L. and Jusko, W.J. (1983). Comp. Prog. Biomed. 16, 203-216.
25. Stoner, G.D. and Mukhtar, H. (1995). J. Cell Biochem. (Suppl.) 22, 169-180.
26. Svensson, C.K. and Knowlton. P.W. (1989). Pharmaceutical Res. 6, 477-480.
27. Tanaka, T. et al. (1988). Jpn. J. Cancer Res. (Gann.) 79, 1297-1303.
28. Vatsis, K.P and Weber, W.W. (1993). Arch. Biochem. Biophys. 301, 71-76.
29. Weber, W.W. et al. (1976). Drug. Metab. Dispos. 4, 94-101.
30. Weber, W.W. and Hein, D.W. (1985). Pharmacol. Review 37, 25-79.
31. Weber, W.W. (1987). Oxford University Press, New York.
32. Yang, H.Y.T. and Neff, H.H. (1976). Neuropharmacol 15, 561-564.
33. Zidek, Z. et al. (1981). Biochem. Pharmacol. 26, 69-70.